Global / Is Everything So Wrong at GSK?
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again…
Altacor
Last updated: 13.02.2014
Address: St John’s Innovation Centre Cowley Road Cambridge CB4 0WS ,United Kingdom
Tel: + 44 (0) 1223 421411
Web: http://tiger.directrouter.co.uk/cgi-sys/defaultwebpage.cgi
Company description
Altacor is an Ophthalmic Specialty Pharmaceutical Company specialising in marketing and development of differentiated products which have been designed for the needs of both ophthalmologists and patients.
From its headquarters in Cambridge UK, Altacor is using its drug development skills and in depth market knowledge to build a portfolio of high quality, differentiated prescription medicines that set new standards in the sector. The company has a sales infrastructure which is active in the secondary care sector and in accessing primary care and promoting the prescription products Clinitas and Clinitas Gel. Altacor is also working in the pharmacy and optical channels through which its OTC products – the Clinitas range for all dry eye conditions, are being promoted.
Altacor’s pipeline consists of development products for Ocular Surface Disease, Ocular Infection and Glaucoma. The company’s products are differentiated by formulation or reprofiling, patented active or delivery systems and presented in multidose or preservative-free single use containers.
Altacor has strong skills in drug formulation, reprofiling and development through its extensive network and understanding of the European regulatory environment which results in a uniquely focused company.
Products and services
Altacor has three areas of therapeutic interest
1. Ocular Surface Disease including Dry Eye syndrome
2. Ocular Infection
3. Glaucoma
Related
Kathy Pritchard-Jones – President, International Society of Paediatric…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the…
Zack Pemberton-Whiteley – CEO, Leukaemia Care
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient…
Europe / Vaccine Wars: What the EU/AstraZeneca Row Shows Us About Pharma Cross-Border Litigation
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and…
UK / Fastest Growing Private Pharmacos; GSK Shake-Up; Brexit Uncertainties; COVID-19 Reinfection Trial
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma…
M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
UK / New Post-Brexit Regulatory Alliance with Australia, Canada, Singapore & Switzerland
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
UK-Japan FTA / Banishing UK Pharma's Brexit Blues
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
UK / MSD to Build USD 1.3 Billion London Research Hub in Boon for Post-Brexit Britain
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Opinion / 3 Ways the UK’s Pharma Sector is Driving Innovation
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
News Roundup / UK Pharma May 2020
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British…
Coronavirus / GSK & Sanofi’s Unprecedented COVID-19 Vaccine Collaboration
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
